Helle Kristine Skjerven

Helle Kristine Skjerven serves as a University Lecturer at the Department of Cancer Treatment, University of Oslo, and concurrently holds the position of Section Chief Physician at Drammen Hospital within Vestre Viken Hospital Trust (Vestre Viken HF). Her dual appointment bridges academic research and frontline clinical oncology practice, with primary focus on breast cancer diagnostics and treatment optimization.

Her research spans molecular profiling for individualized breast cancer therapy, cost-effectiveness analysis of genomic testing, deep learning applications in tumor pathology, and neoadjuvant treatment strategies. She specializes in translating multi-omics data into clinical decision frameworks, particularly for early-stage breast cancer management where genomic tests like Prosigna influence adjuvant therapy choices.

Analysis of her 2024-2025 publications reveals three dominant research thrusts: 1) Validation of AI-driven tumor analysis across cancer types, 2) Prospective multicenter studies on genomic testing impact (EMIT-1 trial), and 3) Development of prognostic subtypes through integrated omics approaches. Her work consistently involves nationwide Norwegian hospital collaborations, reflecting strong emphasis on real-world clinical implementation.

Dr. Skjerven actively contributes to two major research initiatives:

• The national "Use of molecular profiling analysis for individualized treatment decisions in early breast cancer" project involving 58 researchers across 15 Norwegian hospital trusts
• The longitudinal "Breast cancer surgery in Vestre Viken 2007-2016" study examining surgical outcomes

These projects demonstrate her commitment to evidence-based oncology practice through large-scale collaborative research spanning clinical trials, health economics, and translational biomarker studies.